GlucoTrack unit Lōkahi Therapeutics expands ai² platform into three divisions
GCTK•Expansion and new business lines
ai² expanded to 13 universities in about a year, screening more than 45 therapeutic assets; several moved into active diligence.
The new divisions position the platform for partnerships, licensing, fee-based services, workforce programs, and asset origination.
Platform split into three divisions
Lōkahi Therapeutics, a GlucoTrack subsidiary, split its ai² platform into ai² Pipeline, ai² Talent, and ai² Accelerator.
The reorganization targets new revenue lines while maintaining its focus on late-stage therapeutic asset development.
